$TCRT
Alaunos Therapeutics, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022004972 Filed on March 30, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.505M $2.095M $27.56M
YoY Change -57.4% -76.2% -0.37%
% of Gross Profit
Research & Development $5.580M $8.216M $49.64M
YoY Change -58.16% -41.19% -5.79%
% of Gross Profit
Depreciation & Amortization $689.0K $705.0K $2.600M
YoY Change 27.59% 67.86% 136.36%
% of Gross Profit
Operating Expenses $9.085M $10.31M $77.95M
YoY Change -57.87% -54.72% -3.0%
Operating Profit -$9.085M -$77.55M
YoY Change -57.87% -3.5%
Interest Expense -$683.0K -$738.0K -$1.182M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$703.0K -$5.000K -$1.202M
YoY Change -7911.11% -350.0% -412.21%
Pretax Income -$9.788M -$11.79M -$78.75M
YoY Change -54.59% -48.21% -1.53%
Income Tax
% Of Pretax Income
Net Earnings -$9.788M -$11.79M -$78.75M
YoY Change -54.59% -48.21% -1.53%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.37
Diluted Earnings Per Share -$45.54K -$54.94K -$367.3K
COMMON SHARES
Basic Shares Outstanding 216.1M 216.1M 214.4M
Diluted Shares Outstanding 214.9M 214.4M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.26M $76.05M $76.05M
YoY Change -31.78% -33.91% -33.91%
Cash & Equivalents $68.30M $76.05M $76.05M
Short-Term Investments
Other Short-Term Assets $1.517M $1.666M $1.666M
YoY Change -80.16% -84.65% -84.65%
Inventory
Prepaid Expenses
Receivables $0.00 $1.111M $1.111M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $69.77M $78.83M $78.83M
YoY Change -38.1% -39.63% -39.63%
LONG-TERM ASSETS
Property, Plant & Equipment $10.31M $10.94M $15.36M
YoY Change -33.25% 6.94% 3.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $626.0K $631.0K $673.0K
YoY Change 98.73% -15.3% -23.09%
Total Long-Term Assets $15.22M $16.03M $16.03M
YoY Change -3.44% 1.76% 1.76%
TOTAL ASSETS
Total Short-Term Assets $69.77M $78.83M $78.83M
Total Long-Term Assets $15.22M $16.03M $16.03M
Total Assets $84.99M $94.87M $94.87M
YoY Change -33.84% -35.18% -35.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $605.0K $1.368M $1.368M
YoY Change -85.56% 42.5% 42.5%
Accrued Expenses $5.891M $6.076M $6.805M
YoY Change -60.12% -63.37% -60.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.99M $7.868M $7.868M
YoY Change
Total Short-Term Liabilities $21.23M $16.04M $16.04M
YoY Change 11.99% -12.67% -12.67%
LONG-TERM LIABILITIES
Long-Term Debt $10.32M $16.25M $16.25M
YoY Change
Other Long-Term Liabilities $4.312M $0.00 $4.517M
YoY Change 11.42% -100.0% 13.07%
Total Long-Term Liabilities $10.32M $16.25M $20.77M
YoY Change 166.74% 419.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.23M $16.04M $16.04M
Total Long-Term Liabilities $10.32M $16.25M $20.77M
Total Liabilities $35.87M $36.81M $36.81M
YoY Change 57.11% 64.6% 64.59%
SHAREHOLDERS EQUITY
Retained Earnings -$852.6M -$842.9M
YoY Change 10.31%
Common Stock $901.8M $900.9M
YoY Change 1.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.12M $58.06M $58.06M
YoY Change
Total Liabilities & Shareholders Equity $84.99M $94.87M $94.87M
YoY Change -33.84% -35.18% -35.18%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$9.788M -$11.79M -$78.75M
YoY Change -54.59% -48.21% -1.53%
Depreciation, Depletion And Amortization $689.0K $705.0K $2.600M
YoY Change 27.59% 67.86% 136.36%
Cash From Operating Activities -$7.770M -$15.13M -$61.47M
YoY Change -49.26% -11.21% 7.81%
INVESTING ACTIVITIES
Capital Expenditures $29.00K -$359.0K $3.323M
YoY Change -95.96% -90.47% -66.02%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$29.00K -$359.0K -$3.323M
YoY Change -95.96% -90.47% -66.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00 $0.00
YoY Change
Cash From Financing Activities 0.000 -186.0K 25.78M
YoY Change -100.0% -146.5% -74.76%
NET CHANGE
Cash From Operating Activities -7.770M -15.13M -61.47M
Cash From Investing Activities -29.00K -359.0K -3.323M
Cash From Financing Activities 0.000 -186.0K 25.78M
Net Change In Cash -7.799M -15.67M -39.02M
YoY Change -48.05% -23.19% -210.44%
FREE CASH FLOW
Cash From Operating Activities -$7.770M -$15.13M -$61.47M
Capital Expenditures $29.00K -$359.0K $3.323M
Free Cash Flow -$7.799M -$14.77M -$64.79M
YoY Change -51.35% 11.28% -2.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiability
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001107421
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017 tcrt License Agreement Commencement Date
LicenseAgreementCommencementDate
2015-05
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-33038
CY2021 dei Entity Registrant Name
EntityRegistrantName
Alaunos Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
8030 El Rio Street
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
CY2021 dei City Area Code
CityAreaCode
346
CY2021 dei Local Phone Number
LocalPhoneNumber
355-4099
CY2021 dei Security12b Title
Security12bTitle
Common Stock
CY2021 dei Trading Symbol
TradingSymbol
TCRT
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
543706424000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
216127443
CY2021 dei Auditor Name
AuditorName
RSM US LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, MA
CY2021 dei Auditor Firm
AuditorFirmId
49
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76054000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115069000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1111000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
4665000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1666000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10855000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
78831000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
130589000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10941000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10231000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4420000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4650000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
130000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
631000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
745000
CY2021Q4 us-gaap Assets
Assets
94865000
CY2020Q4 us-gaap Assets
Assets
146345000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1368000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
960000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7868000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6076000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16589000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
729000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
819000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16041000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18368000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16250000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4518000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3995000
CY2021Q4 us-gaap Liabilities
Liabilities
36809000
CY2020Q4 us-gaap Liabilities
Liabilities
22363000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
216127443
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
216127443
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
214591906
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
214591906
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
216000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
215000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
900693000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
887868000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-842852000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-764101000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123982000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94865000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146345000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
398000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49643000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52696000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27564000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27665000
CY2021 tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
740000
CY2020 tcrt Property And Equipment And Right Of Use Assets Impairment
PropertyAndEquipmentAndRightOfUseAssetsImpairment
0
CY2021 us-gaap Operating Expenses
OperatingExpenses
77947000
CY2020 us-gaap Operating Expenses
OperatingExpenses
80361000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-77549000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-80361000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1202000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
385000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-78751000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-79976000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78751000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-79976000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214399074
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
209636456
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
95010000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6829000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
442000
CY2020 tcrt Stock Issued During Period Issuance Of Common Stock In Connection With Public Offering
StockIssuedDuringPeriodIssuanceOfCommonStockInConnectionWithPublicOffering
88661000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13016000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-79976000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123982000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10774000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1036000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1016000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-78751000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-78751000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-79976000
CY2021 us-gaap Depreciation
Depreciation
2597000
CY2020 us-gaap Depreciation
Depreciation
1128000
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
740000
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
383000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2021 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
10774000
CY2020 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
6829000
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-3555000
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1335000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9189000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11566000
CY2021 tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
352000
CY2020 tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
2378000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-201000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
635000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
274000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
54000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10512000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5272000
CY2021 tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
434000
CY2020 tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
2462000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61468000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57013000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3323000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9778000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3323000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9778000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
260000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1036000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
442000
CY2021 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
0
CY2020 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
88661000
CY2021 tcrt Net Proceeds From At The Market Stock Offering
NetProceedsFromAtTheMarketStockOffering
0
CY2020 tcrt Net Proceeds From At The Market Stock Offering
NetProceedsFromAtTheMarketStockOffering
13016000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25776000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
102119000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39015000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35328000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115069000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79741000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76054000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115069000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
630000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
0
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
134000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
471000
CY2021 tcrt Warrants Issued In Term Loan
WarrantsIssuedInTermLoan
1016000
CY2020 tcrt Warrants Issued In Term Loan
WarrantsIssuedInTermLoan
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76100000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-842900000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s most significant estimates and judgments used in the preparation of the financial statements are:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trial expenses and other research and development expenses;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration agreements;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value measurements of stock-based compensation; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.86108878960282%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income taxes.</span></div></div>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p>
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
600000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
10774000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
6829000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.62
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.15
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0050
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0136
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0168
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7253
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7480
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7111
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7441
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-78751000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-79976000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
214399074
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
209636456
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34819291
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30479726
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
24118000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7868000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16250000
CY2021Q3 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.045
CY2021 tcrt Interest Expense Amortized Date
InterestExpenseAmortizedDate
2023-08-01
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
1200000
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
16000
CY2021Q4 tcrt Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
66000
CY2020Q4 tcrt Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
199000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18354000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15193000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7413000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4962000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10941000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10231000
CY2021 us-gaap Depreciation
Depreciation
2600000
CY2020 us-gaap Depreciation
Depreciation
1100000
CY2021Q4 tcrt Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1677000
CY2020Q4 tcrt Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4450000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1695000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3298000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
825000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3993000
CY2021Q4 tcrt Accrued Preclinical Services Current
AccruedPreclinicalServicesCurrent
363000
CY2020Q4 tcrt Accrued Preclinical Services Current
AccruedPreclinicalServicesCurrent
749000
CY2021Q4 tcrt Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
1056000
CY2020Q4 tcrt Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
3159000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
227000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
725000
CY2021Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
0
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6076000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16589000
CY2021Q4 us-gaap Operating Lease Residual Value Of Leased Asset
OperatingLeaseResidualValueOfLeasedAsset
1400000
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
600000
CY2021 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
100000
CY2021Q4 tcrt Discounted Risk Adjusted Rates
DiscountedRiskAdjustedRates
0.10
CY2019Q4 tcrt Operating Leases Expiration Month And Year
OperatingLeasesExpirationMonthAndYear
2027-02
CY2020Q2 tcrt Operating Leases Expiration Month And Year
OperatingLeasesExpirationMonthAndYear
2027-02
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1394000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1054000
CY2021 us-gaap Lease Cost
LeaseCost
1394000
CY2020 us-gaap Lease Cost
LeaseCost
1054000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M29D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M8D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1300000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1400000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1102000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1132000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1166000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1201000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1121000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
752000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6474000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1227000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5247000
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
500000
CY2020Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
0
CY2020Q4 tcrt Royalties Amount Payable Thereafter
RoyaltiesAmountPayableThereafter
100000
CY2020Q4 tcrt Expected Cash Payment Payable
ExpectedCashPaymentPayable
1500000
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000
CY2021 us-gaap Severance Costs1
SeveranceCosts1
3657000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
164486000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
147004000
CY2021Q4 tcrt Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
21705000
CY2020Q4 tcrt Deferred Tax Assets Start Up And Organizational Costs
DeferredTaxAssetsStartUpAndOrganizationalCosts
25909000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
39817000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
37183000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
706000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1478000
CY2021Q4 tcrt Deferred Tax Assets Capitalized Acquisition Costs
DeferredTaxAssetsCapitalizedAcquisitionCosts
2946000
CY2020Q4 tcrt Deferred Tax Assets Capitalized Acquisition Costs
DeferredTaxAssetsCapitalizedAcquisitionCosts
3691000
CY2021Q4 tcrt Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1278000
CY2020Q4 tcrt Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1225000
CY2021Q4 tcrt Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
102000
CY2020Q4 tcrt Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
71000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
156000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
135000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
231196000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
216696000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
230119000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
215513000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1077000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1183000
CY2021Q4 tcrt Deferred Tax Liability Right Of Use Asset
DeferredTaxLiabilityRightOfUseAsset
1077000
CY2020Q4 tcrt Deferred Tax Liability Right Of Use Asset
DeferredTaxLiabilityRightOfUseAsset
1183000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1077000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1183000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
297000000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14600000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.03
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.03
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2021 tcrt Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
-0.02
CY2020 tcrt Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp
0
CY2021 tcrt Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
-0.02
CY2020 tcrt Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange
-0.02
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.19
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.24
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
30564
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000000.0
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5842879
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.21
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2222368
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.39
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
338333
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.01
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
886195
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.22
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6840719
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
9380438
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.62
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
363109
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.86
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5192179
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.65
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10665869
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.87
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M1D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4410312
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.85
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M10D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3596315
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.17
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
598000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
30564
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
700000
CY2020 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
500000

Files In Submission

Name View Source Status
0000950170-22-004972-index-headers.html Edgar Link pending
0000950170-22-004972-index.html Edgar Link pending
0000950170-22-004972.txt Edgar Link pending
0000950170-22-004972-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img158989336_0.jpg Edgar Link pending
img158989336_1.jpg Edgar Link pending
img51291522_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcrt-20211231.htm Edgar Link pending
tcrt-20211231.xsd Edgar Link pending
tcrt-20211231_cal.xml Edgar Link unprocessable
tcrt-20211231_def.xml Edgar Link unprocessable
tcrt-20211231_htm.xml Edgar Link completed
tcrt-20211231_lab.xml Edgar Link unprocessable
tcrt-20211231_pre.xml Edgar Link unprocessable
tcrt-ex10_17.htm Edgar Link pending
tcrt-ex10_18.htm Edgar Link pending
tcrt-ex10_19.htm Edgar Link pending
tcrt-ex10_20.htm Edgar Link pending
tcrt-ex10_21.htm Edgar Link pending
tcrt-ex10_22.htm Edgar Link pending
tcrt-ex10_38.htm Edgar Link pending
tcrt-ex10_39.htm Edgar Link pending
tcrt-ex10_40.htm Edgar Link pending
tcrt-ex10_44.htm Edgar Link pending
tcrt-ex10_52.htm Edgar Link pending
tcrt-ex10_53.htm Edgar Link pending
tcrt-ex21_1.htm Edgar Link pending
tcrt-ex23_1.htm Edgar Link pending
tcrt-ex31_1.htm Edgar Link pending
tcrt-ex32_1.htm Edgar Link pending
tcrt-ex3_1.htm Edgar Link pending
tcrt-ex4_6.htm Edgar Link pending
tcrt-ex4_7.htm Edgar Link pending